FDA Study Highlights Variability in Tissue Containment Bag Performance Under Morcellation Forces
- Ark Surgical
- 12 hours ago
- 2 min read
A peer-reviewed study conducted by researchers at the U.S. Food and Drug Administration (FDA) evaluated the performance of commercially available tissue containment bags under conditions simulating laparoscopic power morcellation.
The in vitro study assessed seven legally marketed tissue containment bags using dye and bacteriophage penetration testing to determine their ability to prevent leakage of fluid and cell surrogates. The results demonstrated significant variability in performance across different bag designs, with leakage thresholds ranging widely between products.
Importantly, when clinically relevant forces were incorporated — specifically the combination of insufflation pressure and dynamic forces generated during morcellation — safety margins decreased substantially, and some bags, including composite designs commonly referred to as ‘ripstop’ materials, demonstrated leakage under these conditions.
The study further found that:
Material composition and total thickness alone did not reliably predict performance
Composite (e.g., nylon/polymer “ripstop”) structures may be susceptible to localized defects impacting barrier integrity
Dynamic forces during morcellation can exceed insufflation pressure and meaningfully affect containment performance
Of the systems evaluated, only one had received FDA marketing authorization specifically for use with power morcellation, underscoring the distinction between general-use containment bags and devices validated for this specific application.
Implications for Clinical Practice and Innovation
These findings highlight the importance of rigorous, application-specific testing of tissue containment solutions under realistic procedural conditions. While containment bags are widely used in minimally invasive gynecologic surgery, their performance may differ depending on design, materials, and intended use.
For clinicians, hospitals, and device developers, the study underscores the need to consider:
Performance under dynamic, real-world forces
Alignment between device indication and clinical use
The role of validated testing in supporting safety and efficacy
As minimally invasive techniques continue to evolve, ensuring that supporting technologies are purpose-built, thoroughly evaluated, and aligned with regulatory standards remains essential to advancing surgical safety.
